Nonalcoholic steatohepatitis is liver inflammation and damage caused by a buildup of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. It leads to cirrhosis and increasing risk of liver failure and hepatocellular carcinoma in some cases. The global non-alcoholic steatohepatitis market will reach 9727.96 million USD by 2023 from 4124.74 million USD in 2018 with a CAGR of 13.04% during the period.
Request for Report Sample: https://www.trendsmarketresearch.com/report/sample/3995
Growth by Region
Asia Pacific will grow with high CAGR owing to growth in diagnostic techniques, rise in prevalence NASH and developing healthcare infrastructure. North America held largest share in the market due to prevalence of NASH and presence of pipeline drugs.
Drivers vs Constraints
Increasing cases of diabetics and obesity is the major factor driving the growth of the market. Growth in demand for NASH therapeutics and rise in prevalence of NASH are the factors driving the market. However, lack of diagnostic technologies for NASH is hampering the market growth.
Request for Report Discount: https://www.trendsmarketresearch.com/report/discount/3995
Industry Trends and Updates
AstraZeneca licensed IONIS-AZ6-2.5-LRx, NASH drug from Ionis Pharmaceuticals, Inc. for USD 30 million.
Allergan acquired Tobira Therapeutics Inc. and Akarna Therapeutics Ltd., which provides Allergan a readymade pipeline for the potentially lucrative NASH market.
More Info of Impact [email protected] https://www.trendsmarketresearch.com/report/covid-19-analysis/3995